Zevra Therapeutics (ZVRA) Other Operating Expenses (2019 - 2026)

Zevra Therapeutics (ZVRA) has 6 years of Other Operating Expenses data on file, last reported at $43.3 million in Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.6 million (changed N/A YoY) and the FY2025 annual result came in at $148.3 million, changed N/A from the prior year.
• Other Operating Expenses retreated to $43.3 million in Q1 2026, from $148.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $148.3 million in Q2 2025 to a low of -$23.4 million in Q4 2022.
• A 3-year average of $31.7 million and a median of $10.9 million in 2022 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 1669.4% in 2022, down 39822.03% in 2022.
• Tracing ZVRA's Other Operating Expenses over 3 years: stood at -$23.4 million in 2022, then surged by 732.89% to $148.3 million in 2025, then plunged by 70.8% to $43.3 million in 2026.
• The last three Other Operating Expenses figures came in at $43.3 million (Q1 2026), $148.3 million (Q2 2025), and -$23.4 million (Q4 2022), per Business Quant data.